• ABOUT CALISTOGA
  • Overview
  • Our Corporate values
  • Management Team
  • Board of Directors
  • Investors
• PI3K
  • Overview
  • Hematologic Malignancies
  • Solid Tumors
  • Asthma and COPD
  • Autoimmune Diseases
  • Publications
• PRODUCT PIPELINE
  • Product Pipeline
  • CAL-101
  • CAL-263
  • Isoform-Selective PI3K Inhibitors
• CLINICAL TRIALS
• NEWS & EVENTS
  • Press Releases
  • Media Coverage
  • Events

Calistoga Pharmaceuticals is dedicated to the development of innovative, targeted therapeutics for the treatment of cancer and inflammatory diseases. We are the leader in developing isoform-selective PI3 kinase inhibitors. We are also the first company to demonstrate the clinical benefit of these inhibitors in patients with B cell lymphomas and leukemias.